{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:30:54Z","timestamp":1649057454371},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.medcli.2013.10.012","type":"journal-article","created":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T03:31:03Z","timestamp":1387078263000},"page":"268-274","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuevos f\u00e1rmacos en el tratamiento del mieloma m\u00faltiple"],"prefix":"10.1016","volume":"143","author":[{"given":"Albert","family":"Oriol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.10.012_bib0005","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.10.012_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2004.1.237","article-title":"Multiple myeloma","author":"Harousseau","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.medcli.2013.10.012_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: Clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-10-3366","article-title":"Oncogenomics to target myeloma in the bone marrow microenvironment","volume":"17","author":"Anderson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2013.10.012_bib0025","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2008.325","article-title":"Treatment of newly diagnosed myeloma","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.10.012_bib0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2013.0199","article-title":"Therapeutic advances in relapsed or refractory multiple myeloma","volume":"11","author":"Anderson","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.medcli.2013.10.012_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0045","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.10.012_bib0050","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1080\/10428190701694194","article-title":"Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma","volume":"48","author":"Fenk","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2013.10.012_bib0055","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: Results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.medcli.2013.10.012_bib0065","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0070","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.medcli.2013.10.012_bib0075","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0080","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0085","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1471-2407-12-415","article-title":"Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R\/R MM)","volume":"12","author":"H\u00e1jek","year":"2012","journal-title":"BMC Cancer"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V118.21.301.301","article-title":"Investigational agent MLN9708, an oral proteosome inhibitor, in patients (pts) with relapsed and\/or refractory multiple myeloma (MM): Results from the expansion cohorts of a phase 1 dose-escalation study","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood.V118.21.816.816","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and\/or refractory multiple myeloma: Results from a phase 1 dose-escalation study","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0105","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V118.21.302.302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0115","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0120","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.10.012_bib0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.10.012_bib0130","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.10.012_bib0135","article-title":"Indicaciones terap\u00e9uticas actuales de la talidomida y la lenalidomida","author":"Ordi-Ros","year":"2013","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.10.012_bib0140","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0145","first-page":"4062","article-title":"Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed\/refractory mm: a phase 3, multicenter, randomized, open-label study","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0150","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2011.40.4178","article-title":"Incorporating monoclonal antibodies into the therapy of multiple myeloma","volume":"30","author":"Blad\u00e9","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Van de Donk","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.10.012_bib0160","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1 a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2013.10.012_bib0165","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1182\/blood-2008-10-183772","article-title":"CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells","volume":"113","author":"Tai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0170","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"Van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.medcli.2013.10.012_bib0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0180","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0185","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0190","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J Immunol"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0195","first-page":"654","article-title":"Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma\u2013data from a dose escalation phase I\/II study","volume":"143","author":"Plesner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Van der Veer","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.10.012_bib0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","article-title":"Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma","volume":"152","author":"Hunsucker","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0210","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0215","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.10.012_bib0220","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase i multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.10.012_bib0225","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2013.10.012_bib0230","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.12107","article-title":"Monoclonal antibodies: Potential new therapeutic treatment against multiple myeloma","volume":"90","author":"Allegra","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0235","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2007.15.2546","article-title":"Individualizing treatment of patients with myeloma in the era of novel agents","volume":"26","author":"San-Miguel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0240","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0245","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2011.08664.x","article-title":"Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: Results of a phase 1\/2 study","volume":"153","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0250","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/14796694.3.6.639","article-title":"PI3 kinase\/AKT pathway as a therapeutic target in multiple myeloma","volume":"3","author":"Harvey","year":"2007","journal-title":"Future Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0255","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":"Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I\/II trial","volume":"29","author":"Richardson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.10.012_bib0260","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.leukres.2013.03.006","article-title":"Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma","volume":"37","author":"Richardson","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2013.10.012_bib0265","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.10.012_bib0270","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl 21","key":"10.1016\/j.medcli.2013.10.012_bib0275","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V120.21.1852.1852","article-title":"PANORAMA 2: Panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","volume":"120","author":"Richardson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0280","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.10.012_bib0285","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313007513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313007513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:04:59Z","timestamp":1597205099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313007513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0025775313007513"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.10.012","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevos f\u00e1rmacos en el tratamiento del mieloma m\u00faltiple","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2013.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}